ghk-cu fda approved drug adds non-injectable back to Category 1. FDA Thursday re-added non-injectable GHK-Cu to Category 1 of the 503A bulks process after the nomination was withdrawn from further review. Injectable GHK-Cu remains GHK-Cu (100mg) Research Peptide |

BPC-157 is most commonly used for soft-tissue injury recovery (tendons, ligaments, muscle), chronic tendinopathy, joint discomfort, gut health concerns, and post-surgical tissue repair

Start the provider review Evidence check Useful peptide pages should separate human data, animal research, mechanistic evidence, and marketing claims

As we age, our bodies naturally produce less of key hormones, like growth hormone and testosterone in men

In a 26-week Phase 2 obesity trial, cagrilintide 4.5mg produced a mean body-weight reduction of 10.8%, versus 3.0% on placebo and it outperformed liraglutide 3.0mg (10.8% vs 9.0%)[1]